Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Cited by 104 Publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )
Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )
PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )
J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPwNXBKSzVyPUCuNFYyKM7:TR?=	NH\OS\|ZUSU6JRWK=
ALL-PO	M4TMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\pTWM2OD1yLkC2N\|U2KM7:TR?=	MoSxV2FPT0WU
697	NILEc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEm5O\|Yh\|ryP	NXTS[2FvW0GQR1XS
NCI-H748	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLOOIp4UUN3ME2wMlExOzN2IN88US=>	NET4VXBUSU6JRWK=
NKM-1	M{LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m3V2lEPTB;MD6xNFkyOiEQvF2=	NF;TO2dUSU6JRWK=
ES1	M4n5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mke3TWM2OD1yLkGxNlU2KM7:TR?=	MljOV2FPT0WU
NCI-H1963	NVLUbo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn33TWM2OD1yLkGxOVc6KM7:TR?=	M3zy[HNCVkeHUh?=
NCI-H1417	NW\PbVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMUK5O\|Qh\|ryP	MmPFV2FPT0WU
NEC8	NGTN[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3yZYFKSzVyPUCuNVM2OjdizszN	Mn65V2FPT0WU
CRO-AP2	NYDSTmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnPTWM2OD1yLkG2PFg6KM7:TR?=	MkjkV2FPT0WU
A3-KAW	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjFUFZKSzVyPUCuNVc3OjdizszN	MX7TRW5ITVJ?
SF539	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TxT2lEPTB;MD6xPVU6OyEQvF2=	MVXTRW5ITVJ?
NOS-1	NGLLeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{X4PWlEPTB;MD6xPVYyQSEQvF2=	M{iwcXNCVkeHUh?=
NTERA-S-cl-D1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\YTWlpUUN3ME2wMlIxOTF\|IN88US=>	NVnBVFVQW0GQR1XS
COR-L88	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:0XHdyUUN3ME2wMlIzQTV7IN88US=>	NYHQTHRUW0GQR1XS
EM-2	NH3hOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnjTWM2OD1yLkK0NFc6KM7:TR?=	NFLWV4hUSU6JRWK=
KARPAS-45	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi2NnFKSzVyPUCuNlc5OzNizszN	Mm[2V2FPT0WU
DSH1	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMki3NFgh\|ryP	MlnWV2FPT0WU
HT-144	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\oRldKSzVyPUCuN\|AzPTZizszN	MVrTRW5ITVJ?
ATN-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zafWlEPTB;MD6zNFU4PiEQvF2=	Mn34V2FPT0WU
HEL	M{WxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTtTWM2OD1yLkOxN\|Q5KM7:TR?=	NVvqOppoW0GQR1XS
NB12	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwM{G3OVYh\|ryP	MoL5V2FPT0WU
LU-139	NHvQV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwM{O1NUDPxE1?	NIfoWGJUSU6JRWK=
J-RT3-T3-5	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwM{O3NVYh\|ryP	NVTDPFYxW0GQR1XS
MOLT-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwM{O4NUDPxE1?	MkK3V2FPT0WU
SR	M4K5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jae2lEPTB;MD6zOFI3OSEQvF2=	NG\ze2hUSU6JRWK=
CMK	NFWzZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXycYpMUUN3ME2wMlM2PzJ5IN88US=>	MX7TRW5ITVJ?
ES8	NFu4UlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DFTmlEPTB;MD6zOlAzOiEQvF2=	MX;TRW5ITVJ?
LB647-SCLC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPifGVKSzVyPUCuN\|Y4OyEQvF2=	MVfTRW5ITVJ?
TE-8	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTCXlRKSzVyPUCuN\|Y6OzVizszN	NFTyVJFUSU6JRWK=
BV-173	NWPHUIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn0fJlKSzVyPUCuN\|cyOjFizszN	NU\DS3FbW0GQR1XS
DEL	NWjHeFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nlWGlEPTB;MD6zO\|Q5PyEQvF2=	M{PhOXNCVkeHUh?=
ARH-77	NWfQ[mF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn4cmRZUUN3ME2wMlM5OTl\|IN88US=>	NUXEbpd4W0GQR1XS
NCCIT	M{e4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvDUVFKSzVyPUCuN\|g3PDlizszN	M4nQfXNCVkeHUh?=
RPMI-8402	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzSWld6UUN3ME2wMlM5PzBzIN88US=>	M1X4XHNCVkeHUh?=
MONO-MAC-6	NHmwNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwM{i3O\|Yh\|ryP	MV7TRW5ITVJ?
SK-MM-2	NFH0SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwM{m4Olgh\|ryP	NFr4TmVUSU6JRWK=
CHP-126	NHLLRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNECyN\|Eh\|ryP	MoKxV2FPT0WU
A101D	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn62TWM2OD1yLkSwN{DPxE1?	NHHZNG9USU6JRWK=
SCH	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\J[GlEPTB;MD60NFM1OiEQvF2=	M3TvPHNCVkeHUh?=
NMC-G1	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYiwT\|doUUN3ME2wMlQxOzZ5IN88US=>	MnrTV2FPT0WU
NCI-H209	NWDR[pZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nQV2lEPTB;MD60NFYyOyEQvF2=	MYTTRW5ITVJ?
MOLT-16	M4jOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XxWGlEPTB;MD60NVAyPyEQvF2=	MWDTRW5ITVJ?
RPMI-6666	NF7wU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jrc2lEPTB;MD60NVEzKM7:TR?=	NVfOd3NSW0GQR1XS
OPM-2	NVrXbXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz2TWM2OD1yLkSxOVE{KM7:TR?=	NGjUOIFUSU6JRWK=
MRK-nu-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jLVGlEPTB;MD60N\|E2OyEQvF2=	NYPVbmNiW0GQR1XS
BC-1	M4TOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwNEO0NFMh\|ryP	NYHuRZF5W0GQR1XS
MHH-NB-11	NGD0W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfFUldKSzVyPUCuOFM1PTNizszN	NWPwXXBGW0GQR1XS
Ramos-2G6-4C10	NX;E[JJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwNEO4PVch\|ryP	NUXHXmxXW0GQR1XS
LS-513	NHTxNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfxRlhHUUN3ME2wMlQ1PTBzIN88US=>	M4fORnNCVkeHUh?=
K5	NWe1WHdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHq4Z5pKSzVyPUCuOFcxOjVizszN	MXHTRW5ITVJ?
HOP-62	NFvZT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPQbFNzUUN3ME2wMlQ5OzV6IN88US=>	Mn:xV2FPT0WU
NCI-H187	M3HMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnV[IlYUUN3ME2wMlQ6OjJ5IN88US=>	NF;CWnVUSU6JRWK=
BE-13	M3v5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC2Om9qUUN3ME2wMlQ6PjZzIN88US=>	NHHzRoZUSU6JRWK=
HC-1	M3nKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fDVWlEPTB;MD61NFQ4OyEQvF2=	MVjTRW5ITVJ?
ACN	NH\SbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwNUGwNlgh\|ryP	NH3hUnFUSU6JRWK=
HCC1599	NYG5bWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwNUG1O{DPxE1?	MU\TRW5ITVJ?
MV-4-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\i[otKSzVyPUCuOVMxPDFizszN	NH;keHZUSU6JRWK=
LC-2-ad	M3z1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\UTWlEPTB;MD61N\|Y3OyEQvF2=	MlPpV2FPT0WU
HL-60	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHqTWM2OD1yLkW0NlYyKM7:TR?=	MV;TRW5ITVJ?
NB17	NF;jVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXETWM2OD1yLkW0N\|gh\|ryP	M1XOZXNCVkeHUh?=
TE-1	NX;USoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPZTWM2OD1yLkW1N\|A3KM7:TR?=	MVPTRW5ITVJ?
NCI-H524	M{DET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jOVmlEPTB;MD61OVQxOSEQvF2=	MkjSV2FPT0WU
MZ7-mel	M4LNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDkTWM2OD1yLkW2NVA2KM7:TR?=	NFjpXHJUSU6JRWK=
L-363	M4DuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\GXllKSzVyPUCuOVY3PTdizszN	NIPYUpVUSU6JRWK=
BL-41	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;uTWM2OD1yLkW2PFg6KM7:TR?=	NFHiR4ZUSU6JRWK=
LU-134-A	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTvdXdGUUN3ME2wMlU4ODd\|IN88US=>	NY\n[GxmW0GQR1XS
SIG-M5	NXnpeppQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{T5emlEPTB;MD61O\|g1QCEQvF2=	MnXwV2FPT0WU
ONS-76	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXlbHpCUUN3ME2wMlU5OjR{IN88US=>	MmW5V2FPT0WU
KARPAS-299	M1LX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moe2TWM2OD1yLkW4OVA1KM7:TR?=	M2rY[XNCVkeHUh?=
DU-4475	M1PSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwNUi3NFMh\|ryP	NWPZXpg1W0GQR1XS
NB69	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrxTWM2OD1yLkW5PFI2KM7:TR?=	Mnu4V2FPT0WU
MHH-PREB-1	M1rrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3K5OWlEPTB;MD62NFcyQSEQvF2=	MVnTRW5ITVJ?
LU-165	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXpe\|I2UUN3ME2wMlYyQDF{IN88US=>	NGHVXFlUSU6JRWK=
LOUCY	M{DQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HXTGlEPTB;MD62N\|M3PCEQvF2=	MYPTRW5ITVJ?
NCI-H526	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwNkO1OFEh\|ryP	MkHnV2FPT0WU
KE-37	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3weWhGUUN3ME2wMlY1Ojd4IN88US=>	MX\TRW5ITVJ?
NALM-6	NUHqRlMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnWNWVKSzVyPUCuOlQ5PiEQvF2=	NWDiSHlPW0GQR1XS
CW-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\5[GlEPTB;MD62OVc6PCEQvF2=	MVzTRW5ITVJ?
SU-DHL-1	M3rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDqO4hKUUN3ME2wMlY2QTR5IN88US=>	MXvTRW5ITVJ?
NB13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwNk[4NVch\|ryP	NUnXdVVYW0GQR1XS
QIMR-WIL	NHrqUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDzXHBVUUN3ME2wMlY5OzR\|IN88US=>	MnL6V2FPT0WU
ECC12	NWjzWFZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n1dGlEPTB;MD63NFA5PiEQvF2=	M1ixT3NCVkeHUh?=
KALS-1	NWDaNlF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\BXldKSzVyPUCuO\|A1QTJizszN	MX;TRW5ITVJ?
COR-L279	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTOWZM{UUN3ME2wMlcxQTl4IN88US=>	NE[y[GhUSU6JRWK=
NB14	NVHwRYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;sN\|QzUUN3ME2wMlczPjF5IN88US=>	NUDUUmczW0GQR1XS
CCRF-CEM	M1rKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzo[JlMUUN3ME2wMlc1PjZzIN88US=>	M1naVXNCVkeHUh?=
SW954	NX[1RlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\pSHdKSzVyPUCuO\|U6QTlizszN	MWjTRW5ITVJ?
IST-SL1	NVf5NnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjGTWM2OD1yLke3N\|Q5KM7:TR?=	M{fPWnNCVkeHUh?=
LAMA-84	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LjN2lEPTB;MD63O\|U3PyEQvF2=	MmP3V2FPT0WU
Daudi	NGHnPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHT[4t7UUN3ME2wMlc4PjhzIN88US=>	NVHrb4NmW0GQR1XS
BC-3	M3:xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwN{izNFgh\|ryP	MXTTRW5ITVJ?
HCC2998	NEnoTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwN{izOkDPxE1?	NXHFblhQW0GQR1XS
NCI-H69	NXyxT4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfV[XpJUUN3ME2wMlgxOTR5IN88US=>	MXLTRW5ITVJ?
CPC-N	NX\FSIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDGVYpGUUN3ME2wMlgxPTJ2IN88US=>	MXfTRW5ITVJ?
NOMO-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPUdnl4UUN3ME2wMlgyODh2IN88US=>	NUW1U5R6W0GQR1XS
CESS	NULuV5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nyfmlEPTB;MD64NVE6PyEQvF2=	NIjuUWdUSU6JRWK=
LC4-1	M2nFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HwSmlEPTB;MD64OFAxPyEQvF2=	M4OxfHNCVkeHUh?=
BL-70	NYXLOY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37TVWlEPTB;MD64OVcxOiEQvF2=	MkXFV2FPT0WU
ES4	NYDpd21YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnWU5VKSzVyPUCuPFU5PjhizszN	NUS4SoFSW0GQR1XS
HCE-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjodVRKSzVyPUCuPFcyPzFizszN	MmD3V2FPT0WU
JAR	M1PXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHYRoFKSzVyPUCuPFc5OjdizszN	M{nWN3NCVkeHUh?=
ST486	M3jM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDhTVFKSzVyPUCuPFc6OTdizszN	MWrTRW5ITVJ?
KS-1	NXXSSmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLRTWM2OD1yLki4NFk3KM7:TR?=	MXnTRW5ITVJ?
GDM-1	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M121RWlEPTB;MD64PFY5PyEQvF2=	NWTSZZVsW0GQR1XS
EHEB	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi5TWM2OD1yLkmyOVg2KM7:TR?=	M2jod3NCVkeHUh?=
LB2518-MEL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPMUFRKSzVyPUCuPVMzQDRizszN	Mlu2V2FPT0WU
GOTO	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPZUWlIUUN3ME2wMlk2ODd4IN88US=>	MoHYV2FPT0WU
LXF-289	NVjldW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfXOmp4UUN3ME2wMlk2QTBzIN88US=>	MoX4V2FPT0WU
ES6	NXHsWXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwOU[0N\|ch\|ryP	NI\ESIJUSU6JRWK=
OS-RC-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwOU[4N{DPxE1?	MnTYV2FPT0WU
DMS-153	NWTQe2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwOUe0Olkh\|ryP	NFXNVoFUSU6JRWK=
SK-PN-DW	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nwXWlEPTB;MD65O\|g{OSEQvF2=	MoXOV2FPT0WU
HH	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwOUi5OVkh\|ryP	MUTTRW5ITVJ?
SH-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTlO\|NKSzVyPUGuNFI1OSEQvF2=	NGXsN\|FUSU6JRWK=
MOLT-4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF72W2xKSzVyPUGuNFM1PTRizszN	MVfTRW5ITVJ?
TGW	NF;FPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;jV3JKSzVyPUGuNFc3PzVizszN	M1TWe3NCVkeHUh?=
L-540	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWf4[2ZpUUN3ME2xMlExPjB2IN88US=>	MkXVV2FPT0WU
PF-382	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUe2eldkUUN3ME2xMlEyPTF\|IN88US=>	NUTEdJhKW0GQR1XS
LC-1F	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3O5fmlEPTB;MT6xNlAxPyEQvF2=	NXHEeW0zW0GQR1XS
OVCAR-4	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfn[JBKSzVyPUGuNVMyPjVizszN	MX3TRW5ITVJ?
A4-Fuk	NVPFZ212T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\5TWM2OD1zLkG1N\|Y1KM7:TR?=	MoHXV2FPT0WU
HCC2218	M3vP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTxTWM2OD1zLkG2OlQyKM7:TR?=	NF7xXoJUSU6JRWK=
HAL-01	M{nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrUTZdKSzVyPUGuNVY6PDNizszN	NFLL[ldUSU6JRWK=
IST-MEL1	NUfMWWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPnN\|luUUN3ME2xMlE4PjV7IN88US=>	M3LrZnNCVkeHUh?=
NCI-H719	NFSwUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTFwMUe4PVgh\|ryP	MUjTRW5ITVJ?
EVSA-T	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoL1TWM2OD1zLkG4NVE1KM7:TR?=	M4fOUHNCVkeHUh?=
SK-NEP-1	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3SdWJKSzVyPUGuNlAzPjZizszN	NYDoUFJ7W0GQR1XS
OCUB-M	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n0[WlEPTB;MT6yNVQ5QSEQvF2=	NX;xOGhLW0GQR1XS
MEG-01	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTFwMkKxNVgh\|ryP	M{PrSHNCVkeHUh?=
no-10	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTFwMkOxNVIh\|ryP	NEf4N3NUSU6JRWK=
MHH-CALL-2	NFewfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX4VZlKSzVyPUGuNlQ4OjFizszN	MYHTRW5ITVJ?
SK-N-DZ	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXaTWM2OD1zLkK0O\|c3KM7:TR?=	M2G3RXNCVkeHUh?=
SCLC-21H	NV\CZVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwMk[0O\|gh\|ryP	NVnnbZdqW0GQR1XS
CTV-1	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHNfVdKSzVyPUGuNlc1OjVizszN	NG[xSJJUSU6JRWK=
NB1	NVOydmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL5VJNKSzVyPUGuNlc4OzJizszN	M3jPbXNCVkeHUh?=
NCI-H64	NIPDNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHnTWM2OD1zLkK4OFYzKM7:TR?=	NX6zSGx5W0GQR1XS
MDA-MB-134-VI	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSxTWM2OD1zLkK4OVc4KM7:TR?=	NIr6ZZZUSU6JRWK=
LB2241-RCC	M{L6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwMki2OlMh\|ryP	NF;PfHlUSU6JRWK=
8-MG-BA	NF;S[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwMki4OlYh\|ryP	NEfifXVUSU6JRWK=
LP-1	M1;yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTFwMkm5OFch\|ryP	MWLTRW5ITVJ?
LS-411N	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTFwM{C5PVgh\|ryP	NIjLeYFUSU6JRWK=
CAL-148	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;lT2xUUUN3ME2xMlMzPTR{IN88US=>	M2W5OnNCVkeHUh?=
NCI-H2171	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX76cFdTUUN3ME2xMlM1PTB{IN88US=>	NH3IdnVUSU6JRWK=
JiyoyeP-2003	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnK3TWM2OD1zLkO1N\|kh\|ryP	NWrvS4FvW0GQR1XS
NCI-H2107	NEXENHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\PTWM2OD1zLkO1PFg{KM7:TR?=	NWPnTI9sW0GQR1XS
BB30-HNC	NFy1VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;0O2RiUUN3ME2xMlM5QTd6IN88US=>	NIPVOolUSU6JRWK=
K-562	NYPSSHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwM{myNVkh\|ryP	MU\TRW5ITVJ?
PSN1	NXfJNZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nH[WlEPTB;MT60NlI5PyEQvF2=	MVPTRW5ITVJ?
HCC2157	NWrFXGRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTFwNEK2PVEh\|ryP	NVO3UIlxW0GQR1XS
SBC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwNEK3OFEh\|ryP	NHrGeHJUSU6JRWK=
MC116	M3LORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[5W5pKSzVyPUGuOFM3OTVizszN	NEG4co5USU6JRWK=
KARPAS-422	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTFwNEWzOVgh\|ryP	NUjqTIkxW0GQR1XS
LB996-RCC	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjPTWM2OD1zLkS3NVA{KM7:TR?=	MkHwV2FPT0WU
MSTO-211H	NILWUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXFOXR7UUN3ME2xMlQ4QTh5IN88US=>	NVH0cploW0GQR1XS
BT-474	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTFwNUG3OlQh\|ryP	MWDTRW5ITVJ?
A388	NHHGVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO2b2lKSzVyPUGuOVE6PDVizszN	NFuxSItUSU6JRWK=
SJSA-1	NF;5[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\lSmxtUUN3ME2xMlUzOjZizszN	MYfTRW5ITVJ?
COLO-829	NXjlRplqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEKxe4hKSzVyPUGuOVM2PjRizszN	NGDBeFlUSU6JRWK=
KM-H2	NGjXTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXmTW43UUN3ME2xMlU3PjdizszN	MoP1V2FPT0WU
GR-ST	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL2R5U6UUN3ME2xMlU3QDJizszN	MorVV2FPT0WU
RPMI-8866	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG3UYV[UUN3ME2xMlYxOTR2IN88US=>	MVTTRW5ITVJ?
KG-1	NIH3XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHpSZVuUUN3ME2xMlYyQTBzIN88US=>	Mn[yV2FPT0WU
NCI-H82	M{\ITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\6fHNKSzVyPUGuOlM1ODZizszN	NIjVUWpUSU6JRWK=
LB1047-RCC	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwNkO0OVkh\|ryP	Mnr2V2FPT0WU
KM12	NFi0cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vzXWlEPTB;MT62OFch\|ryP	NU\KSYdKW0GQR1XS
NB5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlGyTWM2OD1zLk[1Olc4KM7:TR?=	NW\ZdZVrW0GQR1XS
HDLM-2	NGHKN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwNkiyPFEh\|ryP	NGnwdo9USU6JRWK=
KU812	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHaV3JKSzVyPUGuOlk3ODVizszN	MkG3V2FPT0WU
DB	NFnifodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofyTWM2OD1zLkewN\|U{KM7:TR?=	MmPxV2FPT0WU
HD-MY-Z	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nkXGlEPTB;MT63OVI{PCEQvF2=	NXP0enVNW0GQR1XS
KURAMOCHI	M1L1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwN{eyNFch\|ryP	MUfTRW5ITVJ?
ETK-1	NIfrVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrkcIpSUUN3ME2xMlc5QDd7IN88US=>	MmPIV2FPT0WU
SK-UT-1	NVvJe\|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPuXGJKSzVyPUGuO\|k{QDhizszN	NHPpSm1USU6JRWK=
HUTU-80	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jPfWlEPTB;MT63PVUxQCEQvF2=	NGT6ZpRUSU6JRWK=
ES7	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTFwOECzNFIh\|ryP	NYP4fXl1W0GQR1XS
SW872	MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILpVoJKSzVyPUGuPFE{QTVizszN	NXTUPXdOW0GQR1XS
TK10	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TtXWlEPTB;MT64N\|ExQCEQvF2=	MX7TRW5ITVJ?
LB831-BLC	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTFwOEO1OlMh\|ryP	NWnrOJcyW0GQR1XS
TE-9	M1XLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTFwOES0NlIh\|ryP	MV;TRW5ITVJ?
MLMA	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPCSppKSzVyPUGuPFgzOzRizszN	NVe0[JJGW0GQR1XS
D-542MG	M4XoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWKyO4ZxUUN3ME2xMlg6Ozd\|IN88US=>	NH:0O3BUSU6JRWK=
EW-16	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvXOlBkUUN3ME2xMlkzPzJizszN	MkTKV2FPT0WU
LOXIMVI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH65TXVKSzVyPUGuPVMzQCEQvF2=	MV3TRW5ITVJ?
GB-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwOUO4OlYh\|ryP	M2PGTnNCVkeHUh?=
IST-SL2	NVrpbnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PLbWlEPTB;Mj6wNFI3OiEQvF2=	Mn7rV2FPT0WU
LAN-6	NHjNcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LUTGlEPTB;Mj6wNVk3PiEQvF2=	NVzV[nBvW0GQR1XS
NCI-H510A	M1flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvlTWM2OD1{LkC0OVAzKM7:TR?=	M{DOV3NCVkeHUh?=
NCI-H1092	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXPOYpIUUN3ME2yMlA2OTJ2IN88US=>	NV7u[pd{W0GQR1XS
HT	NWjrS21WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnuwTWM2OD1{LkGwOFU1KM7:TR?=	M1nUfXNCVkeHUh?=
RL95-2	M2nmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDJRnNwUUN3ME2yMlEyPDh{IN88US=>	NYW4TpE5W0GQR1XS
NCI-H1355	NG\5cJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPKNIlKSzVyPUKuNVE4QTJizszN	NV7q[JVPW0GQR1XS
NCI-H720	NXywNGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJwMU[4O\|Mh\|ryP	MWfTRW5ITVJ?
NCI-H1522	NEfv[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O4SWlEPTB;Mj6yNVczOyEQvF2=	MXnTRW5ITVJ?
LB373-MEL-D	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJwMk[5NFIh\|ryP	NVLWdpZiW0GQR1XS
DG-75	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTJwMkexOFgh\|ryP	M{PFb3NCVkeHUh?=
ML-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEX1[2FKSzVyPUKuN\|I5PTVizszN	MkLBV2FPT0WU
SF126	NGfm[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj5TWM2OD1{LkOzNFk1KM7:TR?=	MUDTRW5ITVJ?
MPP-89	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PhdmlEPTB;Mj6zN\|E1PSEQvF2=	Mnv4V2FPT0WU
NCI-H345	NEjqUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrIWodKSzVyPUKuN\|MzPzdizszN	M{LoTXNCVkeHUh?=
LS-123	NV3MUFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq4Tm5DUUN3ME2yMlM1QTN4IN88US=>	M2\RU3NCVkeHUh?=
NB10	NGDTPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z4OWlEPTB;Mj60NVA6OiEQvF2=	MXvTRW5ITVJ?
CGTH-W-1	NXKyUHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHCbXZRUUN3ME2yMlQzOjZ5IN88US=>	MV3TRW5ITVJ?
CP66-MEL	NYjHU2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTJwNEe3O{DPxE1?	M2XxWnNCVkeHUh?=
L-428	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorWTWM2OD1{LkS4OVIyKM7:TR?=	M4\k[HNCVkeHUh?=
DMS-79	M1PnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX3cmxOUUN3ME2yMlU1OTB\|IN88US=>	M3;WdXNCVkeHUh?=
NCI-H1882	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTJwNke1OlIh\|ryP	NXHEfZRsW0GQR1XS
KGN	M1vjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTJwN{[4O\|Yh\|ryP	MkHkV2FPT0WU
EW-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjGU5NKSzVyPUKuO\|cxQDNizszN	NE\CbVVUSU6JRWK=
U-266	M3\3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HEcGlEPTB;Mj64OFgzOyEQvF2=	NVPHTZZpW0GQR1XS
COLO-320-HSR	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDyWoRnUUN3ME2yMlg2PjRzIN88US=>	NV\yR3VLW0GQR1XS
KMOE-2	M3HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfMb2F1UUN3ME2yMlg4PzFzIN88US=>	MYfTRW5ITVJ?
BB49-HNC	NUHkSHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXHTWM2OD1{LkmyOFgh\|ryP	NIHB[plUSU6JRWK=
GI-1	NXzmUm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzBXlc1UUN3ME2yMlkzQTV5IN88US=>	MnjnV2FPT0WU
NCI-H1304	M1S5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTmcWZKSzVyPUOuNFA2OTFizszN	MU\TRW5ITVJ?
NCI-H2227	NFTNWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfYUmV3UUN3ME2zMlAzODd7IN88US=>	Mni4V2FPT0WU
U-87-MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTrTWM2OD1\|LkCzOVE{KM7:TR?=	NF;BS2JUSU6JRWK=
NCI-H747	NG\lVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILa[5dKSzVyPUOuNFUzODZizszN	MVrTRW5ITVJ?
CTB-1	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK1U3hTUUN3ME2zMlA2Ozd4IN88US=>	Mne3V2FPT0WU
RPMI-8226	M4\PW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTNwMUSzO\|gh\|ryP	NGLXSm1USU6JRWK=
NCI-H2141	Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[4VGtKSzVyPUOuNVY2PjZizszN	MkLhV2FPT0WU
IST-MES1	NWG4bIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjURpNKSzVyPUOuNVgzPzlizszN	MnOwV2FPT0WU
TE-5	M{O0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXnUHlKSzVyPUOuNlE{PDJizszN	NITDU4VUSU6JRWK=
UACC-257	NF32epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXn3[Zg{UUN3ME2zMlQ{PjV7IN88US=>	NHriRmFUSU6JRWK=
SK-N-FI	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTNwNEWyNlch\|ryP	M2XQZnNCVkeHUh?=
MFH-ino	M{nwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNwNE[1PFkh\|ryP	NEGyfXNUSU6JRWK=
SF268	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr5T\|lQUUN3ME2zMlQ5OTd2IN88US=>	NV24[5R1W0GQR1XS
TE-12	NUPNdYE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrlPZdmUUN3ME2zMlUyPjl7IN88US=>	M3rRUnNCVkeHUh?=
NB6	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3HRZVHUUN3ME2zMlU2PTZ\|IN88US=>	M2\ROXNCVkeHUh?=
DJM-1	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNwNUm4PVkh\|ryP	NGHQfnhUSU6JRWK=
MZ1-PC	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zNdGlEPTB;Mz62NVYzPCEQvF2=	NUDUZY5uW0GQR1XS
OCI-AML2	MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnaWZozUUN3ME2zMlYzPjdzIN88US=>	NULMem1NW0GQR1XS
NCI-H1155	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfsXnppUUN3ME2zMlcxQTR5IN88US=>	M3r1eXNCVkeHUh?=
RKO	NXq4WpFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nsT2lEPTB;Mz63O\|E5QSEQvF2=	MXPTRW5ITVJ?
ECC4	M2[5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL5V2tLUUN3ME2zMlk4OTl3IN88US=>	Mm\EV2FPT0WU
BB65-RCC	NX7VdnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjFWGRKSzVyPUOuPVc2PDdizszN	MUjTRW5ITVJ?
EB-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVu5XVR6UUN3ME2zMlk6PjN\|IN88US=>	MXnTRW5ITVJ?
SHP-77	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2n5T2lEPTB;ND6wNFUzPCEQvF2=	M2K5fnNCVkeHUh?=
NCI-H2196	NEPld3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LiXmlEPTB;ND6wOVYzPSEQvF2=	MVLTRW5ITVJ?
GI-ME-N	M3rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWC2XVJ4UUN3ME20MlA3Ozl7IN88US=>	MoLJV2FPT0WU
MN-60	NIOzUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n0WWlEPTB;ND6xNFg4KM7:TR?=	MlPpV2FPT0WU
NCI-H1694	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTRwMUO0NFUh\|ryP	NF;MOVJUSU6JRWK=
LU-65	M{fxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTRwMUWzN\|Ih\|ryP	M3vTc3NCVkeHUh?=
NCI-H1436	NILifpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PmTGlEPTB;ND6xPFM{OyEQvF2=	M3nJOHNCVkeHUh?=
KINGS-1	NWHQOopHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj5bXhKSzVyPUSuN\|E1OzJizszN	NV\sdlFZW0GQR1XS
GT3TKB	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;XR2szUUN3ME20MlM{OjZ6IN88US=>	Ml32V2FPT0WU
Becker	NYLOT417T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDocWpKSzVyPUSuN\|c{OTJizszN	NIfQZpRUSU6JRWK=
HCC1187	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPOS4loUUN3ME20Mlg6PjV5IN88US=>	MYnTRW5ITVJ?
D-502MG	NIq2XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLMS2VKSzVyPUWuNFA1OTZizszN	NWnod2pUW0GQR1XS
VA-ES-BJ	M{TBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXyWIR2UUN3ME21MlE{Pzd6IN88US=>	M3T0WHNCVkeHUh?=
NB7	NUHvXGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjtOldKSzVyPUWuNVQyOTJizszN	MWDTRW5ITVJ?
SW962	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTVwM{i4NVQh\|ryP	MmG3V2FPT0WU
no-11	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf4TWM2OD13Lke2N\|Q{KM7:TR?=	Ml7FV2FPT0WU
KNS-81-FD	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwOUC2PVQh\|ryP	MWrTRW5ITVJ?
COLO-684	NILQN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTVwOUm0PVQh\|ryP	M1LxUnNCVkeHUh?=
D-263MG	NVHrTI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3OzWGlEPTB;Nj6wPFg6PSEQvF2=	M3Tie3NCVkeHUh?=
EW-24	NIP5W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvPRnp4UUN3ME22MlI5PTFizszN	M1n1S3NCVkeHUh?=
TE-10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTqbGxKSzVyPU[uOFI3OjNizszN	M4TYTHNCVkeHUh?=
EKVX	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1SxO2lEPTB;Nj60OlMzOSEQvF2=	M{jJOnNCVkeHUh?=
NCI-H1648	NIXCWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3SwOWlEPTB;Nj62O\|U2PyEQvF2=	MnfHV2FPT0WU
LB771-HNC	NWXL[FNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTJe\|J1UUN3ME22MlkzOzBzIN88US=>	NWn3WllNW0GQR1XS
SK-MEL-1	M1rXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnOxTWM2OD16LkGzNVY3KM7:TR?=	NX7RUJNQW0GQR1XS
COLO-668	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnWTWM2OD16LkK3O\|g3KM7:TR?=	NFzkRplUSU6JRWK=
EW-12	NVfDWHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHpc2RKSzVyPUiuOFA5ODNizszN	NYSxW4pQW0GQR1XS
A253	NITJbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvpS2RKSzVyPUiuPFQ3PjFizszN	MmmyV2FPT0WU
NCI-H2126	MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPiTo9yUUN3ME24Mlg6OzF7IN88US=>	NI\EOnpUSU6JRWK=
Calu-6	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRThwOUmwOFIh\|ryP	M2PjSnNCVkeHUh?=
NCI-H23	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTlwMUe3OFYh\|ryP	MV7TRW5ITVJ?
WSU-NHL	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTmNmZJUUN3ME25Mlc4PDd6IN88US=>	NG\FdIdUSU6JRWK=
MMAC-SF	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTlwOUe5NFQh\|ryP	NXP0T4Z1W0GQR1XS
SK-LMS-1	NH3DNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnjPZdLUUN3ME2xNE4zQDN2IN88US=>	MnjKV2FPT0WU
GCIY	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\UTlhKSzVyPUGwMlU6OjRizszN	NEHZ[HRUSU6JRWK=
TE-15	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTFzLk[wNFQh\|ryP	Mlm2V2FPT0WU
EoL-1-cell	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTFzLke2PFIh\|ryP	M{[2N3NCVkeHUh?=
NCI-H2081	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTFzLke3PFYh\|ryP	NWjhTJZYW0GQR1XS
EW-3	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLaTWM2OD1zMj6yOFY{KM7:TR?=	M3\PUXNCVkeHUh?=
CAS-1	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mli2TWM2OD1zMj6zOlMyKM7:TR?=	MUDTRW5ITVJ?
C2BBe1	M3[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTF{Lk[xN\|Eh\|ryP	MkTHV2FPT0WU
D-247MG	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTF{Lke5OVIh\|ryP	Mkf4V2FPT0WU
NCI-SNU-5	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nheWlEPTB;MUKuPFAyOyEQvF2=	MUPTRW5ITVJ?
LS-1034	M2G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT1N4RKSzVyPUG0MlM6PzVizszN	MmPvV2FPT0WU
EW-18	NEjaSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqwNHhSUUN3ME2xOE41PDhizszN	MnfZV2FPT0WU
Raji	M3;ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7UOXU4UUN3ME2xOE42ODR7IN88US=>	MkPMV2FPT0WU
D-283MED	NIDYNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTF2Lk[yO\|Eh\|ryP	M1j0cnNCVkeHUh?=
MZ2-MEL	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTF2Lkm2PVYh\|ryP	MkHsV2FPT0WU
NCI-SNU-16	NHLlT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTF3LkS2N\|Mh\|ryP	NV:5V4dnW0GQR1XS
P30-OHK	NF7UbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjUSWxZUUN3ME2xO{44QDNzIN88US=>	NIrKenRUSU6JRWK=
RXF393	NFjzeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jOdGlEPTB;MUmuNFE5PiEQvF2=	NGPzU3ZUSU6JRWK=
NCI-H1395	NEDpVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTJyLk[3NFMh\|ryP	NH\0XpRUSU6JRWK=
U-698-M	M1zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HCbWlEPTB;MkCuO\|A4PSEQvF2=	M3vISXNCVkeHUh?=
NCI-SNU-1	NVnUb2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7rTWM2OD1{MD63NlI{KM7:TR?=	NV3pNVRKW0GQR1XS
SW684	NVPMTGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL3PHNKSzVyPUKxMlE4OTZizszN	M2L1THNCVkeHUh?=
NCI-H716	M4LVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVuxWIszUUN3ME2yNU4{OTV2IN88US=>	NVywUodkW0GQR1XS
JVM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTJzLkSxN\|Mh\|ryP	M3XPfHNCVkeHUh?=
NCI-H1581	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTtSFlKSzVyPUKyMlQyPDhizszN	NE\SWmxUSU6JRWK=
CA46	NFTNW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjjZXJEUUN3ME2zNU43QTN4IN88US=>	NXr5UFVMW0GQR1XS
SNB75	M1PUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTN\|Lk[1NFMh\|ryP	M2PzeHNCVkeHUh?=
KNS-42	NW\QWnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\IXWlEPTB;M{WuPVYzPCEQvF2=	MorXV2FPT0WU
TUR	NGfUW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTN4LkC1NlEh\|ryP	NEXnZ2FUSU6JRWK=
REH	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlWyTWM2OD1\|Nz64NlEyKM7:TR?=	M2fRZ3NCVkeHUh?=
EW-22	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\YTWM2OD12Mj6yPFg2KM7:TR?=	M4G4V3NCVkeHUh?=
NCI-H446	M4LWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DOWmlEPTB;NEKuO\|g2OyEQvF2=	MYnTRW5ITVJ?
ES3	NHTofJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPqTWM2OD12Mz6xN\|M6KM7:TR?=	MYXTRW5ITVJ?
EW-11	M3\4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTR2LkiyNVgh\|ryP	NGDa[4xUSU6JRWK=
RH-1	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\uTWM2OD12Nz61PFEzKM7:TR?=	MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	+ Expand Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	+ Expand Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80 Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SNDX-275

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 104 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 104 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)